Kadcyla: payments to doctors
Payments that named Kadcyla as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $5M
- Providers
- 3,771
- Transactions
- 9,159
- Average per transaction
- $543
The per-transaction average — $543 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,771 providers the average total is $1,319, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $3,506,157 | 70.5% |
| Genentech USA, Inc. | $1,322,241 | 26.6% |
| F. Hoffmann-la Roche AG | $140,727 | 2.8% |
| Chugai Pharmaceutical Co., Ltd. | $3,808 | 0.1% |
| Hoffmann-la Roche Limited | $1,320 | 0.0% |
| Roche Products Limited | $232 | 0.0% |